Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
### Primary Indications
* Gastroesophageal reflux disease (GERD)
* Erosive esophagitis healing and maintenance
* Zollinger-Ellison syndrome
* H. pylori eradication (in combination regimens)
* Prevention of NSAID-induced gastric ulcers in patients at risk
### Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily for 4-8 weeks. For maintenance of healing, 40 mg orally once daily may be continued; some patients may be managed on 20 mg orally once daily.
* **Zollinger-Ellison Syndrome:** 40 mg orally or intravenously once daily. Doses may be titrated up to 240 mg daily, divided into doses as needed. The maximum dose is typically 240 mg per day.
* **H. pylori Eradication:** 40 mg orally twice daily for 7-14 days in combination with antibiotics (e.g., amoxicillin and clarithromycin or metronidazole and clarithromycin).
* **NSAID-induced Ulcer Prevention:** 20 mg or 40 mg orally once daily.
### Pediatric Dosing
* **GERD/Erosive Esophagitis:**
* **1 month to 5 years:** 10 mg orally once daily. Doses up to 20 mg orally once daily have been used.
* **5 years to 16 years:** 20 mg orally once daily for GERD; 40 mg orally once daily for erosive esophagitis. Doses up to 40 mg or 80 mg orally once daily have been used.
* **Note:** Dosing in pediatric patients is often based on weight and may vary. Consult specific pediatric guidelines.
### Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 20 mg orally or intravenously once daily.
### Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
### Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
* **Serious:** *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with prolonged use, hypomagnesemia (can be severe), vitamin B12 deficiency, and potential for increased risk of certain infections (e.g., pneumonia).
### Key Drug Interactions
* **Warfarin:** May increase INR and prothrombin time. Monitor INR closely.
* **Certain Antiretrovirals (e.g., rilpivirine, atazanavir):** PPIs can decrease absorption. Avoid coadministration.
* **Methotrexate:** PPIs may increase methotrexate levels. Consider interruption of pantoprazole.
* **Drugs Dependent on Gastric pH for Absorption (e.g., ketoconazole, itraconazole, iron salts):** PPIs can decrease absorption.
### Monitoring
* **Long-term use:** Monitor for vitamin B12 deficiency and hypomagnesemia.
* **Patients at risk for osteoporosis:** Consider bone density monitoring.
* **Patients taking warfarin:** Monitor INR.
* **If symptoms persist or worsen:** Re-evaluate diagnosis and treatment.
### Clinical Pearls
* Pantoprazole is available in oral and intravenous formulations.
* Oral suspension and delayed-release tablets are available. Delayed-release tablets should be swallowed whole and not chewed or crushed.
* For IV administration, reconstituted solution should be used within a specified timeframe.
* Long-term use of PPIs should be reserved for conditions requiring it, with the lowest effective dose.
***
**Disclaimer:** This information is for educational purposes only and does not substitute for professional medical advice. Always consult with a qualified healthcare provider to determine the best course of treatment for your specific condition. Review the most current prescribing information and guidelines before making any treatment decisions.
